<DOC>
	<DOCNO>NCT00002208</DOCNO>
	<brief_summary>To demonstrate antiviral activity safety/tolerability test regimen indinavir equivalent control regimen indinavir coadministered zidovudine ( ZDV ) ( stavudine , d4T ) lamivudine ( 3TC ) 24 week protease inhibitor- 3TC-naive HIV-1-seropositive patient . To characterize steady-state pharmacokinetic profile indinavir , ZDV ( d4T ) , 3TC presence , control test regimen group .</brief_summary>
	<brief_title>A Multicenter , Open-Label , Randomized , 24-Week Study Compare Safety Activity Indinavir Sulfate , 800 Mg q 8 h Versus 1,200 Mg q 12 h Combination With Zidovudine 3TC</brief_title>
	<detailed_description>Patients randomize 1 2 arm : Arm A : Indinavir plus ZDV plus 3TC . Arm B : Indinavir ( test dose ) plus ZDV plus 3TC . NOTE : d4T may substitute zidovudine toxicity management . Patients stratify base prior use nucleoside analog ( naive v experience ZDV , dideoxyinosine [ ddI ] , dideoxycytidine [ ddC ] , d4T ) screen viral RNA result ( low 50,000 copies/mL v 50,000 copies/mL ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV1 seropositive status . CD4 count great 100 cells/mm3 . Viral RNA 10,000 copies/mL . Consent parent guardian le 18 year age . Exclusion Criteria Prior Medication : Excluded : Prior therapy protease inhibitor . Prior therapy 3TC .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2003</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
</DOC>